In light of indications from FDA that it has put on hold, if not fully abandoned, finalizing its controversial and long-awaited regulatory framework guidance on laboratory-developed tests (LDTs), industry experts say there are other approaches agency could look at to achieve the same or similar objectives.
Last week, stakeholders received a message from FDA that the LDT guidance would not be released this year. Instead, the agency says it plans to work with industry and Congress...